ARTICLE SUMMARY:
Although 2018 sales of Boston Scientific’s current interventional oncology products were barely worth a mention in recent financial disclosures, it hopes, with the acquisition of BTG, to become a significant player in oncology to help sustain the growth investors are now expecting.
As it awaits the closing of its acquisition of British device company BTG plc, Boston Scientific Corp. is positioning its burgeoning oncology business as foundational to the company’s future growth.
